Samsung Biologics has announced an all-cash offer valued at 1.46 billion Swiss francs (approximately $1.8 billion) to acquire Switzerland-based PolyPeptide Group, marking the largest acquisition in the company's history as it expands its footprint in the fast-growing peptide therapeutics market.
Under the proposed deal, PolyPeptide shareholders will receive 44.31 Swiss francs per share. The transaction is expected to close by the end of 2026, subject to regulatory approvals and shareholder acceptance.
The acquisition underscores Samsung Biologics' long-term strategy to diversify beyond its core biologics manufacturing business and strengthen its position in peptide-based active pharmaceutical ingredients (APIs). Demand for peptide therapies has surged globally, driven by the rapid adoption of GLP-1 medicines used to treat obesity and type 2 diabetes.
By acquiring PolyPeptide, Samsung Biologics aims to expand its capabilities in the development and manufacturing of peptide-based medicines while offering pharmaceutical partners a broader portfolio of contract development and manufacturing services.
PolyPeptide's Board of Directors has unanimously recommended the offer. Chairman Peter Wilden said the proposal delivers an attractive cash valuation for shareholders while providing certainty following the company's strategic review process.
The acquisition will also significantly expand Samsung Biologics' global manufacturing and research network. PolyPeptide operates production and research facilities in Switzerland, Sweden, Belgium, France, the United States, and India, giving Samsung a stronger international presence and additional capacity to serve pharmaceutical clients worldwide.
Founded in 1996 as a spin-off from pharmaceutical company Ferring, PolyPeptide has become one of the world's leading developers and manufacturers of peptide-based active pharmaceutical ingredients. The company has produced more than 1,000 therapeutic peptides for global pharmaceutical customers across a wide range of disease areas.
Despite a modest decline in Samsung Biologics' share price following the announcement, analysts view the acquisition as a strategic investment that positions the company to benefit from the rapidly expanding peptide therapeutics market. With demand for obesity and diabetes treatments expected to remain strong, the deal is seen as enhancing Samsung Biologics' long-term growth prospects and strengthening its competitive position in the global biopharmaceutical industry.
Must Read:-
